Statements about mechanism describe pathways reported in published animal and in vitro work. Human evidence varies.
Weight loss without muscle preservation is a hollow victory. Two compounds, semaglutide and AOD-9604, sit at opposite ends of the regulatory spectrum. One is an FDA-approved medicine with a defined safety record. The other is a peptide fragment sold as a research chemical, not cleared for human use by any major regulator. This article compares what the published literature says about each compound's effect on lean mass during weight loss, strictly within a research-information frame.
What is the regulatory status of semaglutide and AOD-9604?
Semaglutide holds marketing authorisation from the FDA, EMA, and other agencies for type 2 diabetes and, under certain brand names, chronic weight management. It is a prescription drug subject to pharmacovigilance requirements. AOD-9604, by contrast, has no marketing approval from the FDA, EMA, or TGA. It is listed as a research peptide and is not intended for human administration. Researchers conducting independent work should follow institutional protocols and ethics review where applicable.
The distinction matters because safety data for semaglutide come from large, randomised, controlled trials. A 2021 trial enrolled close to 2,000 participants. For AOD-9604, human evidence is sparse and mostly confined to small, early-phase studies. The literature on AOD-9604 suggests some lipolytic activity in animal models, but no robust human trial has confirmed muscle-sparing effects.
How does semaglutide affect lean mass during weight loss?
Semaglutide is a GLP-1 receptor agonist. It reduces body weight primarily by lowering energy intake. Published research shows that weight lost with semaglutide includes both fat mass and fat-free mass. A 2021 analysis of the STEP 1 trial reported that roughly 40% of total weight lost was lean mass. That proportion is consistent with other forms of diet-induced weight loss.
Lean mass loss matters because it can lower resting metabolic rate and affect physical function. The 2022 review of GLP-1 agonists noted that the ratio of lean to fat loss does not appear worse than what is seen with lifestyle intervention alone. Still, the absolute amount of lean mass lost can be clinically meaningful in older adults or those with sarcopenia. Semaglutide and bone health are also linked, as rapid weight loss can affect bone density, though fracture data remain reassuring.
What does the research say about AOD-9604 and muscle preservation?
AOD-9604 is a fragment of human growth hormone (hGH) that is reported to retain the lipolytic domain of the parent molecule without stimulating IGF-1. Early animal work from the late 1990s showed that AOD-9604 could reduce body fat in obese rodents without affecting lean mass. A 2013 human study, small in scale, suggested some fat loss but did not demonstrate a statistically significant preservation of lean tissue.
The mechanism is thought to involve stimulation of beta-3 adrenergic receptors on adipose tissue. Published research indicates that AOD-9604 does not appear to promote cell proliferation or raise blood glucose, which are concerns with full-length hGH. However, the absence of large, long-term trials means there is no reliable estimate of how much lean mass, if any, is spared during weight loss with AOD-9604. The data are too thin to draw firm conclusions.
Can semaglutide be combined with other peptides to protect muscle?
Some researchers have explored whether adding a growth hormone secretagogue might offset semaglutide-related lean mass loss. Tesamorelin, a GHRH analogue approved for HIV-associated lipodystrophy, has been studied in this context. A 2022 phase 2 trial combined semaglutide with tesamorelin and reported a trend toward better lean mass preservation, though the difference did not reach statistical significance.
CJC-1295 and hexarelin are also mentioned in the literature as agents that can increase pulsatile GH release. Published research shows that CJC-1295 can elevate IGF-1 levels for several days after a single dose. Hexarelin, a GHRP, has been shown to increase lean mass in animal models. None of these combinations have been approved by regulators. The safety of stacking unapproved peptides with an approved drug is unknown. Semaglutide vs retatrutide comparisons show that newer triple agonists may naturally yield better body composition outcomes, but those are still under investigation.
What about retatrutide and other emerging agents?
Retatrutide is a GIP/GLP-1/glucagon receptor triagonist currently in phase 3 trials. A 2023 phase 2 study reported that retatrutide produced weight loss in the neighbourhood of 24% at the highest dose, with a lean mass proportion that appeared similar to semaglutide. The glucagon component may increase energy expenditure, which could theoretically improve the fat-to-lean loss ratio.
Published research on retatrutide is still limited to a few hundred participants. The 2023 data suggest that lean mass loss, as a percentage of total weight lost, was around 30-40%. That range overlaps with semaglutide. Whether retatrutide will prove superior for body composition awaits larger and longer trials. Sex differences in semaglutide weight loss also highlight that men and women may lose lean mass at different rates, a factor that will need to be accounted for in future studies of any weight-loss agent.
Is AOD-9604 a legal alternative to semaglutide?
AOD-9604 is not approved for human use in any jurisdiction. It is sometimes marketed as a dietary supplement or research peptide, but regulators have issued warnings. The FDA has sent warning letters to companies selling AOD-9604 as a supplement, stating that it does not meet the definition of a dietary ingredient. In Australia, the TGA has similarly clarified that AOD-9604 is a prescription-only medicine, yet no product has been approved.
Semaglutide, when prescribed, is obtained through a pharmacy with a valid prescription. The legal pathway is clear. For AOD-9604, the lack of regulatory approval means there is no oversight of manufacturing quality, purity, or sterility. Researchers who purchase AOD-9604 for laboratory studies must verify the source independently. There is no legal route for personal use.
What does the evidence say about muscle-sparing strategies during weight loss?
Regardless of the agent used, the literature consistently points to three interventions that can reduce lean mass loss: adequate protein intake, resistance exercise, and a gradual rate of weight loss. A 2018 meta-analysis of weight-loss trials found that protein intakes above 1.2 g/kg/day were associated with better lean mass retention. Resistance training, performed two to three times per week, can attenuate the loss of muscle during caloric restriction.
These strategies apply whether weight loss is achieved with semaglutide, lifestyle changes, or bariatric surgery. Published research shows that combining pharmacotherapy with structured exercise yields better body composition outcomes than either approach alone. The 2022 review emphasised that clinicians should prescribe exercise alongside GLP-1 agonists to mitigate lean mass loss. Protecting bone density during menopause is another concern where exercise and nutrition play a key role.
How do the safety profiles compare?
Semaglutide's safety profile is well characterised. Common adverse events include nausea, vomiting, diarrhoea, and constipation. Serious risks, such as pancreatitis and gallbladder disease, are rare but documented. The FDA label includes a boxed warning for thyroid C-cell tumours based on rodent studies. AOD-9604 has no equivalent safety database. Animal studies have not raised major safety signals, but the absence of evidence is not evidence of absence.
Because AOD-9604 is not approved, there is no standardised adverse event reporting system. Any side effects that occur in people who obtain it outside of a clinical trial are not systematically captured. This makes it impossible to compare safety profiles in a meaningful way. The precautionary principle would suggest that the known risks of semaglutide are preferable to the unknown risks of an unapproved peptide.
Which compound is better for preserving lean mass?
On the current evidence, semaglutide has a large body of data showing that lean mass loss is proportional to total weight loss and comparable to other effective interventions. AOD-9604 lacks the human data to make any claim about muscle preservation. The theoretical appeal of a lipolytic fragment that spares muscle has not been translated into clinical proof.
For researchers interested in body composition, the choice is not between these two agents. It is about designing protocols that minimise lean mass loss regardless of the weight-loss method. Published research points to diet and exercise as the most reliable tools. Pharmacotherapy can be a useful adjunct, but only when used within its approved indication and under medical supervision. The regulatory status of AOD-9604 precludes its consideration as a therapeutic option.